Amneal Pharmaceuticals 관리
관리 기준 확인 4/4
Amneal Pharmaceuticals CEO는 Chirag Patel, Jan2005 에 임명되었습니다 의 임기는 19.83 년입니다. 총 연간 보상은 $ 2.37M, 31.6% 로 구성됩니다. 31.6% 급여 및 68.4% 보너스(회사 주식 및 옵션 포함). 는 $ 196.23M 가치에 해당하는 회사 주식의 7.04% 직접 소유합니다. 196.23M. 경영진과 이사회의 평균 재임 기간은 각각 5.3 년과 6.5 년입니다.
주요 정보
Chirag Patel
최고 경영자
US$2.4m
총 보상
| CEO 급여 비율 | 31.6% |
| CEO 임기 | 19.8yrs |
| CEO 소유권 | 7.0% |
| 경영진 평균 재임 기간 | 5.3yrs |
| 이사회 평균 재임 기간 | 6.5yrs |
최근 관리 업데이트
Recent updates
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Nov 10
Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success
Jul 10Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Apr 15Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?
Mar 19Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry
Dec 28Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company
Dec 10Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Nov 28Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt
Sep 24Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?
Aug 08Amneal Pharmaceuticals Could Have An Upbeat Q2
Jul 10These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively
Apr 18Amneal Pharmaceuticals: Risk Still Persists
Jan 23Amneal Pharma reaffirms 2022 guidance
Jan 10Amneal joins hands with Orion to commercialize generic products in Europe and more countries
Jan 04Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load
Dec 20Amneal Pharmaceuticals large shareholder TPG cuts stake
Dec 14FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203
Nov 11Amneal Pharmaceuticals Q3 2022 Earnings Preview
Nov 03Amneal Pharmaceuticals: A Small 'Thumbs Up'
Oct 28Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet
Sep 01Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment
Aug 31Amneal Pharmaceuticals Q2 2022 Earnings Preview
Aug 04CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$184m |
| Jun 30 2024 | n/a | n/a | -US$175m |
| Mar 31 2024 | n/a | n/a | -US$169m |
| Dec 31 2023 | US$2m | US$750k | -US$84m |
| Sep 30 2023 | n/a | n/a | US$10m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | -US$135m |
| Dec 31 2022 | US$5m | US$750k | -US$130m |
| Sep 30 2022 | n/a | n/a | -US$132m |
| Jun 30 2022 | n/a | n/a | -US$134m |
| Mar 31 2022 | n/a | n/a | US$2m |
| Dec 31 2021 | US$5m | US$724k | US$11m |
| Sep 30 2021 | n/a | n/a | US$14m |
| Jun 30 2021 | n/a | n/a | US$9m |
| Mar 31 2021 | n/a | n/a | -US$17m |
| Dec 31 2020 | US$2m | US$1 | US$91m |
| Sep 30 2020 | n/a | n/a | US$62m |
| Jun 30 2020 | n/a | n/a | -US$194m |
| Mar 31 2020 | n/a | n/a | -US$199m |
| Dec 31 2019 | US$446k | US$44k | -US$362m |
| Sep 30 2019 | n/a | n/a | -US$339m |
| Jun 30 2019 | n/a | n/a | -US$67m |
| Mar 31 2019 | n/a | n/a | -US$69m |
| Dec 31 2018 | US$325k | n/a | -US$21m |
보상 대 시장: Chirag 의 총 보상 ($USD 2.37M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 6.55M ).
보상과 수익: Chirag 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Chirag Patel (57 yo)
19.8yrs
테뉴어
US$2,370,385
보상
Mr. Chirag K. Patel has been Co-Chief Executive Officer, President and Director of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as D...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 19.8yrs | US$2.37m | 7.04% $ 196.2m | |
| Co-Founder | 22.8yrs | US$2.37m | 8.16% $ 227.6m | |
| Executive VP & CFO | 4.7yrs | US$1.89m | 0.17% $ 4.8m | |
| Senior VP | 2.8yrs | US$1.35m | 0.019% $ 516.4k | |
| Executive VP & Chief Human Resources Officer | 10.8yrs | US$1.53m | 0.094% $ 2.6m | |
| Executive VP & Chief Commercial Officer of Generics | 6.8yrs | US$1.94m | 0.083% $ 2.3m | |
| Head of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Corporate Development | 1.8yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP of Strategic Sourcing & Supply Management | 1.8yrs | 데이터 없음 | 데이터 없음 | |
| Chief Quality Officer | 5.8yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Scientific Officer of Generics | 4.8yrs | 데이터 없음 | 데이터 없음 | |
| Vice President & Head of Medical Affairs | no data | 데이터 없음 | 데이터 없음 |
5.3yrs
평균 재임 기간
54.5yo
평균 연령
경험이 풍부한 관리: AMRX 의 관리팀은 노련하고 경험 (평균 재직 기간 5.3 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 19.8yrs | US$2.37m | 7.04% $ 196.2m | |
| Co-Founder | 22.8yrs | US$2.37m | 8.16% $ 227.6m | |
| Independent Chairman of the Board | 5.3yrs | US$299.08k | 0.24% $ 6.6m | |
| Independent Director | 6.5yrs | US$302.20k | 0.085% $ 2.4m | |
| Independent Director | 6.5yrs | US$244.70k | 0.097% $ 2.7m | |
| Independent Director | 4.9yrs | US$254.70k | 0.079% $ 2.2m | |
| Independent Director | 4.9yrs | US$277.20k | 0.087% $ 2.4m | |
| Director | 6.5yrs | US$217.20k | 0.66% $ 18.5m | |
| Independent Director | 2.3yrs | US$267.04k | 0.030% $ 841.3k | |
| Independent Director | 6.5yrs | US$217.20k | 0.081% $ 2.3m | |
| Independent Director | 4.9yrs | US$284.70k | 0.083% $ 2.3m |
6.5yrs
평균 재임 기간
57yo
평균 연령
경험이 풍부한 이사회: AMRX 의 이사회는 경험(평균 재직 기간 6.5 년)으로 간주됩니다.